Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cell.2014.08.016 http://scihub22266oqcxt.onion/10.1016/j.cell.2014.08.016 C4237931!4237931!25201530     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell 2014 ; 159 (1): 176-87 Nephropedia Template TP {{tp|p=25201530|t=2014. Organoid cultures derived from patients with advanced prostate cancer |pdf=|usr=}}{{25201530}} gab.com Text Organoid cultures derived from patients with advanced prostate cancer JO: Cell http://www.kidney.de/pget.php?&tw=1&pmid=25201530 #FOAvip The lack of in vitro prostate cancer models that recapitulate the diversity of human prostate cancer has hampered progress in understanding disease pathogenesis and therapy response. Using a 3D ?organoid? system, we report success in long-term culture of prostate cancer from biopsy specimens and circulating tumor cells. The first seven fully characterized organoid lines recapitulate the molecular diversity of prostate cancer subtypes, including TMPRSS2-ERG fusion, SPOP mutation, SPINK1 overexpression and CHD1 loss. Whole exome sequencing shows a low mutational burden, consistent with genomics studies, but with mutations in FOXA1 and PIK3R1, as well as of DNA repair and chromatin modifier pathways that have been reported in advanced disease. Loss of p53 and RB tumor suppressor pathway function are the most common feature shared across the organoid lines. The methodology described here should enable the generation of a large repertoire of patient-derived prostate cancer lines amenable to genetic and pharmacologic studies. Twit Text FOAVip Organoid cultures derived from patients with advanced prostate cancer ????Cell http://www.kidney.de/pget.php?&tw=1&pmid=25201530 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25201530 #FOAvip English Wikipedia <ref>{{Cite pmid|25201530}}</ref> Organoid cultures derived from patients with advanced prostate cancer #MMPMID25201530 Gao D; Vela I; Sboner A; Iaquinta PJ; Karthaus WR; Gopalan A; Dowling C; Wajala JN; Undvall EA; Arora VK; Wongvipat J; Kossai M; Ramazanoglu S; Barboza LP; Di W; Cao Z; Zhang QF; Sirota I; Ran L; MacDonald TY; Beltran H; Mosquera JM; Touijer KA; Scardino PT; Laudone VP; Curtis KR; Rathkopf DE; Morris MJ; Danila DC; Slovin SF; Solomon SB; Eastham JA; Chi P; Carver B; Rubin MA; Scher HI; Clevers H; Sawyers CL; Chen Y Cell 2014[Sep]; 159 (1): 176-87 PMID25201530show ga The lack of in vitro prostate cancer models that recapitulate the diversity of human prostate cancer has hampered progress in understanding disease pathogenesis and therapy response. Using a 3D ?organoid? system, we report success in long-term culture of prostate cancer from biopsy specimens and circulating tumor cells. The first seven fully characterized organoid lines recapitulate the molecular diversity of prostate cancer subtypes, including TMPRSS2-ERG fusion, SPOP mutation, SPINK1 overexpression and CHD1 loss. Whole exome sequencing shows a low mutational burden, consistent with genomics studies, but with mutations in FOXA1 and PIK3R1, as well as of DNA repair and chromatin modifier pathways that have been reported in advanced disease. Loss of p53 and RB tumor suppressor pathway function are the most common feature shared across the organoid lines. The methodology described here should enable the generation of a large repertoire of patient-derived prostate cancer lines amenable to genetic and pharmacologic studies. äOrganoid cultures derived from patients with advanced prostate cancer (epmc).pdf DeepDyve Pubget Overpricing